Hannuo Medical Secures Nearly RMB 1 Billion in Additional Funding to Advance Diversified ECLS Product Portfolio and Global Expansion

VCBeat has learned that Shenzhen Lifemotion Medical Technology Co., Ltd. (“Lifemotion”) recently secured nearly RMB 100 million in investment. This round was jointly invested by Shenzhen Hongtu Medical Health Industry Equity Investment Fund Partnership (L.P.), managed by Shenzhen Capital Group Co., Ltd. (“SCGC”), Shenzhen Capital Co., Ltd., and the Shenzhen Bao’an District Industrial Investment Guidance Fund.This is a follow-on financing round for Lifemotion, following its over RMB 100 million Series E funding completed in late December 2023., which also marks the second round of investment by the Shenzhen Hongtu Medical Health Industry Equity Investment Fund Partnership (L.P.) in Lifemotion, following its initial investment in 2022.

Lifemotion, founded in 2018, is a global medical device R&D company specializing in extracorporeal life support technologies. It has been only six years since its establishment.Achieved breakthroughs in core key technologies for extracorporeal life support, enabling independent control and mass production of core product components.On January 4, 2023, the company’s independently developed first domestically produced extracorporeal membrane oxygenation (ECMO) system received market approval. In July, two additional core products—the disposable centrifugal pump head and the disposable long-lasting membrane oxygenator—were also approved. Following their launch, all four products were rapidly promoted and adopted across China.

It is reported that Lifemotion’s Lifemotion^®ECMO System—Since the Debut of the First Domestically Produced Complete ECMO System,It has been clinically applied in over a hundred hospitals across China, successfully treating hundreds of patients, with a total operational time exceeding tens of thousands of hours.As the first domestic brand to achieve a breakthrough in the complete ECMO system and ensure a stable supply of full ECMO consumables, it has gained widespread market recognition in a short period, effectively breaking the import monopoly. With the future decentralization and expanded coverage of critical care medical resources, domestic ECMO brands will continue to benefit. According to data from Yifangbao, a third-party bidding software, domestic manufacturers represented by Lifemotion accounted for nearly 30% of the newly added ECMO market in China in 2023, with their market share rising further in the first quarter of 2024.Domestic ECMO manufacturers are gradually replacing imported ones, becoming a major force in China's ECMO market.

In vitro organoid life-support medical devices represent a high-growth sector with significant expansion potential. Due to extremely high technical barriers, lengthy R&D cycles, and stringent requirements for manufacturing precision, the global market has long been dominated by a few international medical giants. In the long term, the industry chain for in vitro organoid life-support devices offers substantial development potential and a high growth ceiling. Core products, upstream core material technologies, and downstream medical services are still in their early stages of development. Given the considerable challenges associated with technological breakthroughs, first-mover companies will maintain a strong competitive advantage over the long term.

After launching China’s first complete ECMO system, Lifemotion continues to leverage its core foundational technologies in artificial heart and lung support. The company is developing more than ten high-value Class III medical devices tailored for critical clinical scenarios in cardiology, pulmonology, intensive care, and emergency medicine. These efforts aim to overcome technological bottlenecks and enhance the competitiveness of domestic brands. This strategy not only addresses the longstanding challenge of “urgent clinical demand coupled with supply shortages” but also enables the company to enter high-growth niche markets through product diversification. By competing and collaborating with international counterparts, Lifemotion helps drive the rapid and healthy development of the extracorporeal life support industry.The company also began laying the groundwork for overseas markets last year, promoting domestic brands and products to the international market.

Lifemotion Chairman Liu YangIt indicates that the ecological development of the extracorporeal life support (ECLS) industry and the advancement of its clinical applications represent a trend toward high-quality development across the entire healthcare sector. In recent years, the company has closely aligned with national policies, persisting in innovation and R&D within this specialized niche. Following the launch of the first domestically produced complete ECMO system, the company continues to develop multiple high-value Class III medical devices while accelerating its global expansion, with overall progress proceeding smoothly. We have consistently adhered to the three developmental stages and principles of “Focus,” “Persevere,” and “Secure.” Specifically, we maintain “Focus” on the ECLS track driven by clinical needs and domestic innovation; we “Persevere” through the “difficult” early commercialization phase characterized by long R&D cycles and substantial resource investment amidst a changing macro environment; and we successfully “Secure” our market position amid the growing adoption of domestic products and global layout trends.

Dr. Zhou Yi, General Manager of SCGC Health Industry FundStatement: In alignment with the national strategic directive to “integrate technological innovation resources, lead the development of strategic emerging industries and future industries, and accelerate the formation of new quality productive forces,” our team continuously monitors domestic “Little Giant” enterprises with potential for technological innovation and explosive growth. We are committed to discovering and nurturing innovative value, covering the entire corporate lifecycle. As the first Chinese enterprise to achieve a breakthrough in the complete ECMO system, Lifemotion has demonstrated robust clinical applications since its market launch. Its persistent adherence to “undertaking difficult yet correct endeavors” has been well-validated by the market. By continuing to deepen indigenous innovation in this niche sector, Lifemotion exhibits a strong trajectory and promising prospects characterized by continuous breakthroughs and advancement typical of innovative enterprises.

Shenzhen Capital Group was established in 1999 with capital contributed by the Shenzhen Municipal Government, which also guided social capital investment. With a mission to discover and empower great enterprises, the Group is committed to identifying and nurturing innovative value. It has evolved into a comprehensive investment group centered on venture capital, boasting a registered capital of RMB 10 billion and managing assets totaling approximately RMB 477.5 billion. Due to its outstanding performance in the venture capital sector, Shenzhen Capital Group ranked first among domestic venture capital firms in the Zero2IPO China Venture Capital Institution Annual Rankings from 2016 to 2022.